-
Amgen/Roche Strategic ESA Partnership + The Imminent Threat of Pfizer’s ESA Biosimilar: Who Will Win in the US?
Epoetin alfa and follow-on generation agents are collectively known as erythropoietin stimulating agents (ESAs), and for many years, these agents have been the standard of care to treat the anemia...
-
Challenges of Accessing and Analyzing Real World Data
Thinking about getting started in real world data? Here are the challenges you should be aware of before you begin. There continues to be a great deal of buzz around real world data. For...
-
Market Event Recap: FDA Ad Com Meeting to Discuss Cordis’ INCRAFT Stent Graft System
The FDA Circulatory System Devices Panel met on June 12, 2018 to provide advice, make recommendations, and vote on the premarket approval application by Cordis for its INCRAFT Stent Graft...
-
Mega-IDNs Rattle Payer Landscape: As Dominant Provider Systems Gain Control, MCOs Fight Back
This live session took place on Thursday, June 14th 2018. There has been a marked uptick in the trend of employers bypassing traditional insurers to contract with integrated delivery networks for...
-
ASCO 2018 Highlights: Key Oncology Landscape Updates and Implications for the Life Sciences Industry
DRG Oncology experts joined nearly 40,000 oncology professionals at the 2018 Annual Meeting to get a download of the latest data and innovations in the space. Out of the many sessions and abstracts we...
-
Metastatic Castrate Resistant Prostate Cancer Global Forecast
In 2017 there were an estimated 322,000 drug treatable patients worldwide with Metastatic Castrate Resistant Prostate Cancer. Over the next decade, growth in the number of first-line cases will...
-
Current Immune Checkpoint Inhibitors - Late-Phase Clinical Trials
Immune checkpoint inhibitors continue to revolutionize the current clinical oncology landscape. DRG experts used Oncology Clinical Trial Monitor data to provide an overview of the late-phase immune...
-
CAR T-cell Therapy Pipeline and Forecast Snapshot
CD19-targeted CAR T cells – Kymriah and Yescarta – herald a new era and paradigm shift in cancer treatment. Novartis and Gilead paved way for bringing this cutting-edge technology to patients who...
-
Mapping the Clinical Path in Ulcerative Colitis With Real World Data
Real World Data has the potential to boost brand performance, fine-tune commercial strategy, tease out subtle market nuances, and unlock hidden opportunities. The below infographic utilizes US claims...
-
How Pharma Can Differentiate in the Value-Driven Market
Multiple market disruptions are shaking up the healthcare value chain and underscoring the need for pharma companies demonstrate value in order to differentiate and build relationships with customers...
A global consultancy and training agency providing market leading product & portfolio strategy, health economic outcomes research & evidence generation, value communication and training services across the life science industry.
We partner with both the biopharmaceutical and medical technology industry to support commercialization & patient access across a variety of functions including: R&D, commercial strategy, HEOR, market access, new product planning, marketing, data insights & analytics, business development and channel & segment customer engagement.
